1217 related articles for article (PubMed ID: 11950011)
1. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral administration of malathion on the course of disease in MRL-lpr mice.
Rodgers KE
J Autoimmun; 1997 Aug; 10(4):367-73. PubMed ID: 9237800
[TBL] [Abstract][Full Text] [Related]
3. Reversing interleukin-2 inhibition mediated by anti-double-stranded DNA autoantibody ameliorates glomerulonephritis in MRL-lpr/lpr mice.
Song YC; Tang SJ; Lee TP; Hung WC; Lin SC; Tsai CY; Ng WV; Wu MF; Sun KH
Arthritis Rheum; 2010 Aug; 62(8):2401-11. PubMed ID: 20506162
[TBL] [Abstract][Full Text] [Related]
4. [Effects of HS1-associated protein X-1 on the lupus activities: experiment with MRL/lpr lupus-like mice].
Zhai ZF; Zhou CL; Zhong BY; Ao JH; Hao F
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(6):406-10. PubMed ID: 18581896
[TBL] [Abstract][Full Text] [Related]
5. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice.
Fujii T; Okada M; Fujita Y; Sato T; Tanaka M; Usui T; Umehara H; Mimori T
J Autoimmun; 2009 Sep; 33(2):125-34. PubMed ID: 19596182
[TBL] [Abstract][Full Text] [Related]
7. FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice.
Ando S; Amano H; Amano E; Minowa K; Watanabe T; Nakano S; Nakiri Y; Morimoto S; Tokano Y; Lin Q; Hou R; Ohtsuji M; Tsurui H; Hirose S; Takasaki Y
Biochem Biophys Res Commun; 2010 Apr; 394(3):804-10. PubMed ID: 20233577
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
Cash H; Relle M; Menke J; Brochhausen C; Jones SA; Topley N; Galle PR; Schwarting A
J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
[TBL] [Abstract][Full Text] [Related]
9. The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRL lpr/lpr mice.
Apelgren LD; Bailey DL; Fouts RL; Short L; Bryan N; Evans GF; Sandusky GE; Zuckerman SH; Glasebrook A; Bumol TF
Cell Immunol; 1996 Oct; 173(1):55-63. PubMed ID: 8871601
[TBL] [Abstract][Full Text] [Related]
10. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus.
Gutierrez-Ramos JC; Andreu JL; Revilla Y; Viñuela E; Martinez C
Nature; 1990 Jul; 346(6281):271-4. PubMed ID: 1973822
[TBL] [Abstract][Full Text] [Related]
11. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice.
Tchorbanov AI; Voynova EN; Mihaylova NM; Todorov TA; Nikolova M; Yomtova VM; Chiang BL; Vassilev TL
Eur J Immunol; 2007 Dec; 37(12):3587-96. PubMed ID: 18034421
[TBL] [Abstract][Full Text] [Related]
12. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FAS(lprcg)/FAS(lprcg) mice.
Yasuda T; Yoshimoto T; Tsubura A; Matsuzawa A
Cell Immunol; 2001 Jun; 210(2):77-86. PubMed ID: 11520074
[TBL] [Abstract][Full Text] [Related]
13. Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration.
Licht R; van Bruggen MC; Oppers-Walgreen B; Rijke TP; Berden JH
Arthritis Rheum; 2001 Jun; 44(6):1320-30. PubMed ID: 11407691
[TBL] [Abstract][Full Text] [Related]
14. Treatment with testosterone or estradiol in melatonin treated females and males MRL/MpJ-Faslpr mice induces negative effects in developing systemic lupus erythematosus.
Jimenez-Caliani AJ; Jimenez-Jorge S; Molinero P; Rubio A; Guerrero JM; Osuna C
J Pineal Res; 2008 Sep; 45(2):204-11. PubMed ID: 18507713
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice.
Liu CP; Tsai WJ; Shen CC; Lin YL; Liao JF; Chen CF; Kuo YC
Eur J Pharmacol; 2006 Feb; 531(1-3):270-9. PubMed ID: 16413531
[TBL] [Abstract][Full Text] [Related]
16. C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice.
Wenderfer SE; Ke B; Hollmann TJ; Wetsel RA; Lan HY; Braun MC
J Am Soc Nephrol; 2005 Dec; 16(12):3572-82. PubMed ID: 16207826
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
18. B7 costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-b7.1/B7.2 blocking antibodies.
Liang B; Gee RJ; Kashgarian MJ; Sharpe AH; Mamula MJ
J Immunol; 1999 Aug; 163(4):2322-9. PubMed ID: 10438978
[TBL] [Abstract][Full Text] [Related]
19. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice.
Nicoletti F; Di Marco R; Zaccone P; Xiang M; Magro G; Grasso S; Morrone S; Santoni A; Shoenfeld Y; Garotta G; Meroni P
Eur J Immunol; 2000 Feb; 30(2):438-47. PubMed ID: 10671199
[TBL] [Abstract][Full Text] [Related]
20. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses.
Hou LF; He SJ; Li X; Yang Y; He PL; Zhou Y; Zhu FH; Yang YF; Li Y; Tang W; Zuo JP
Arthritis Rheum; 2011 Aug; 63(8):2445-55. PubMed ID: 21484768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
